ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Pooled it
- Human leukocyte antigen pharmacogenetics in infectious diseases: anti-infective drug toxicity and host immune response.Frontiers in pharmacology · 2026Review
- Persistent elite controllers as the key model to identify permanent HIV remission.Current opinion in HIV and AIDS · 2025Review
- Plasma proteomics analysis of Chinese HIV-1 infected individuals focusing on the immune and inflammatory factors afford insight into the viral control mechanism.Frontiers in immunology · 2024Article
- Association of TREX1 polymorphism with disease progression in human immunodeficiency virus type-1 (HIV-1) infected patients.Virus genes · 2023Article
- Article
- The Role of Innate Immunity in Natural Elite Controllers of HIV-1 Infection.Frontiers in immunology · 2022Review
- Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection.PloS one · 2022Article
- Naïve CD4BMC immunology · 2021Article
- Article
- Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4AIDS research and therapy · 2020Article
- Article
- Dynamics in HIV-DNA levels over time in HIV controllers.Journal of the International AIDS Society · 2019Article
- Current Treatment Options for HIV Elite Controllers: a Review.Current treatment options in infectious diseases · 2018Article
- AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.Viruses · 2018Review
- Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome.Cytokine & growth factor reviews · 2018Review
- Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.Journal of virology · 2018Article
- Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers.BMC medicine · 2018Article
- Article
- Association of Diverse Genotypes and Phenotypes of Immune Cells and Immunoglobulins With the Course of HIV-1 Infection.Frontiers in immunology · 2018Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HIV-1-controllers maintain HIV-1 viremia at low levels (normally <2000 HIV-RNA copies/mL) without antiretroviral treatment. However, some HIV-1-controllers have evidence of immunologic progression with marked CD4 Methods: We analysed the association of interferon lambda 4 (IFNL4)-related polymorphisms and HLA-B haplotypes within Long Term Non-Progressor HIV-1-controllers ((LTNP-C), defined by maintaining CD4 Conclusions: We have defined genetic markers able to segregate stable HIV-1-controllers from those who experience CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.